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LETTERS TO THE EDITORRegarding “Cost-effectiveness analysis of elective
endovascular repair compared with open surgical
repair of abdominal aortic aneurysms for patients
at a high surgical risk: A 1-year patient-level
analysis conducted in Ontario, Canada”
A 1-year economic evaluation study comparing endovascular
aneurysm repair (EVAR) with open surgical repair (OSR) for the
management of abdominal aortic aneurysms (AAAs) in patients at a
high surgical risk supported that EVAR may be a cost-effective ther-
apeutic option for high-risk patients undergoing elective AAA repair
(total average 1-year costs: $34,146 vs. $34,170, respectively;Pnot
significant).1 Compared with OSR, EVAR was associated with lower
initial hospitalization costs ($31,181 vs. $28,139, respectively; P 
not significant) but significantly higher follow-upmedical expenses at
1 year ($2,171 vs. $5,172, respectively, P .05).1
A possible limitation that may lead to the support of incorrect
and/or biased conclusions is the duration of this study (1 year).1
This may already be suspected from the comparison of the 1-year
follow-up medical expenses; although the initial hospitalization
expenses were not significantly different for the 2 procedures,
EVAR had considerably higher 1-year follow-up costs.1
The cost-effectiveness of EVAR may be hampered by the
development of long-term complications (e.g. endoleaks, stent
migrations, graft-limb thromboses, and graft stenoses).2 An exten-
sive systematic review and comparative assessment of the 2 proce-
dures for the elective repair of AAAs showed that a large percentage
of the complications following EVAR occurs after the first year.2
For example, although the incidence of type I endoleaks at 1 year was
3.5% (range, 0-14%; 13 studies [n  2,544 patients]), the same
incidence rose to 6.7% (range, 0%-21.5%) beyond the first year (18
studies [n 7,848 patients]).2 Similar results were reported for stent
migration rates; although the 1-year stent migration rate was1% (3
studies [n1,599 patients]), 4.4% of the patients demonstrated stent
migration1 year following EVAR (range, 1.7%-18.9%; 8 studies [n
 7,027 patients)].2 Finally, whereas the 1-year incidence of graft-
limb thrombosis was 2.5% (range, 0%-11%; 11 studies [n  1,657
patients]), this incidence increased to 3.8% (range, 1.9%-6.1%; 8
studies [n 6,602 patients]) after the first year.2
Another issue which increases the long-term costs of EVAR is
the need for long-term (if not life-long) surveillance.3 A study
comparing the follow-up costs of patients undergoing EVAR vs.
OSR for elective AAA repair showed that not only is EVAR more
expensive at the 1-year follow-up ($17,640 vs. $14,122, respec-
tively; P .001), but also that this cost discrepancy increases with
a longer follow-up period (average follow-up cost per year: $999
vs. $55, respectively; P  .001).3
In high-risk patients undergoing elective AAA repair, EVAR is
probably associated with improved mortality rates compared with
OSR (1-year all-cause mortality rates: 7.1% vs. 17.3%, respectively;
P  .04).1 However, there is compelling evidence2-4 suggesting
that, after taking into consideration the need for long-term surveil-
lance, EVAR may not be as cost-effective as OSR for the manage-
ment of patients undergoing elective AAA repair, including those
individuals at a high surgical risk.
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In this 1-year Canadian study among high-risk patients, the
1-year medical costs were similar between endovascular aneurysm
repair (EVAR) and open surgical repair (OSR) ($33,311 vs
$33,352, respectively) while the 1-year mortality rates were signif-
icantly lower in EVAR patients (7.1% vs 17.3%). Based on boot-
strap techniques to deal with sampling uncertainty, the probability
of EVAR being cost-effective was 0.76 and 0.9 if society was
willing to spend $50,000 per life year gained (LYG) or $100,000/
LYG, respectively.1
In a sensitivity analysis, we extrapolated the 1-year mortality
rate observed in our trial to a 5-year time horizon. We assumed
long-term routine follow-up costs to EVAR only and several
re-intervention rates (5%, 10%, and 20%) in EVAR patients to
reflect an increased risk of long-term complications following
EVAR. We also used different assumptions regarding mortality
convergence. In the least favorable scenario (convergence of mor-
tality rate at 2 years and re-intervention rate of 20%), the incremen-
tal cost-effectiveness ratio of EVAR compared with OSR in high-
risk patients was $14,968/LYG and $38,720/QALY. Based on
these results, we concluded that “EVAR may be a cost-effective
strategy in high-risk patients.” Our conclusion also stated that
“longer term data are needed to decrease the uncertainty associ-
ated with the results”.1
We agree with Dr Paraskevas that it is very important to model
the long-term costs and consequences associated with EVAR and
OSR. We recognize, as outlined in the discussion, that our extrap-
olations to a 5-year time horizon did not fully take into account the
development and management of long-term comorbidities and
differences in quality of life. However, we believe that our assump-
tions were conservative and favored OSR (eg, no follow-up cost or
need for re-intervention in OSR patients).
To evaluate the long-term cost-effectiveness of EVAR and
OSR in Canada, the authors recently developed a 10-year Markov
model based on a systematic literature review and Canadian cost
data. Based on commonly cited threshold, EVARwas not found to
be cost-effective compared with OSR.2 However, this study, like
other previous economic studies, was based on data from a mixed
population of low- and high-risk patients. As such, these findings
may not be generalizable to high-risk patients.
We also recently published a review aimed at evaluating trends
over time in EVAR vs OSR. Included in this review were 84
comparative studies (57,645 patients) of which six were random-
ized trials and 78 were nonrandomized trials. Eight nonrandom-
ized comparative studies specifically examined only high-risk pa-
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January 2009278 Letters to the Editortients (N  684 patients). When compared with all patients (N 
75 studies), high-risk patients had lower odds ratio (EVAR/OSR)
of cardiac, pulmonary, and renal problems. Lower rates of type I
endoleak or conversion were also observed in high-risk patients.3
Other results indicated that EVAR outcomes had improved over
time as previously reported by Frank et al.4
We continue collecting data on these high-risk patients to
evaluate the midterm outcomes associated with EVAR and OSR,
which will confirm if EVAR is cost-effective in high-risk patients
based on longer-term data.
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Regarding “Symptomatic acute occlusion of the
internal carotid artery: Reappraisal of urgent vascular
reconstruction based on current stroke imaging”
Weis-Müller et al reported a single-center experience with
surgical revascularization of acute extracranial internal carotid ar-
tery (ICA) occlusion in the acute stage.1 In the Discussion section,
they cited our previous article2 and stated “Nowadays interven-
tional teams are also dealing with acute ICA occlusion. The largest
series was actually presented by a Taiwanese group, who treated 30
patients with acute cervical ICA occlusion by using endovascular
techniques.” After comparing with our results, they concluded
that it is better to treat cervical ICA occlusion surgically. We think
that there are a number of issues that need to be clarified.
Firstly, our series included endovascular recanalization at-
tempts only in patients with either recurrent neurologic deficit or
objective ipsilateral hemisphere ischemia after ICA occlusion doc-
umentation. Mean duration from occlusion documentation to the
procedure was 179  254 days (ranging from 56 to 1309 days).2
Therefore, the ICA occlusions were “chronic”, instead of “acute”
in our report.
Secondly, as the authors mentioned, the success of surgery in
acute carotid occlusion depends on the duration of the occlusion.Their success rate in recanalizing ICA occlusion was 86% in pa-
tients with occlusion duration less than 72 hours. In contrast, Paty
et al3 reported a low success rate of only 34% in 90 ICA occlusions
within 14 days from symptom onset. Therefore, the role of surgery
for ICA occlusion should be limited in the very acute stage. Our
report, on the other hand, demonstrated an acceptable success rate
of 73% in endovascular recanalization for chronic ICA occlusion, in
which setting surgery has been proven ineffective.4 With the ad-
vance of device and skill, endovascular recanalization for ICA
occlusion, in both acute and chronic stage, may become the
treatment of choice in the future.
Irrespective of these issues, Weis-Müller et al are to be ac-
knowledged for applying diffusion/perfusion mismatch in select-
ing patients who may potentially benefit from urgent revascular-
ization. We believe that using imaging modalities to identify
viability/ischemia is crucial in clinical judgment for patients with
ICA occlusion, in both acute1 and chronic2 stages, and further
studies are mandatory to prove this concept.
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We thank Dr Kao very much for his interesting comment.
Indeed, his series of 30 chronic carotid occlusions reopened by
endovascular technique1 cannot be compared with our series of 35
acute carotid occlusions reopened surgically.2 After reading his
article, we misinterpreted his series of carotid occlusions “acute”
because time interval elapsed after carotid occlusion was not de-
fined precisely. In the section “patient selection,” he wrote: “the
most recent cerebral infarction, if documented, should be at least 2
weeks before intervention.” We concluded that his strategy is to
wait 2 weeks after symptomatic carotid occlusion before starting
with his intervention. Now we understand that his indication for
intervention is different from ours. His intention is to treat recur-
rent neurological symptoms caused by chronic carotid occlusion.
On the contrary, we want to reopen acutely occluded carotid
arteries to safe brain from enlarging infarction and to prevent
neurologic disturbances caused by carotid occlusion. Until re-
cently, it was not generally accepted that reopening a chronically
occluded internal carotid artery (ICA) is a safe way of enhancing
cerebral perfusion, but his results show that endovascular tech-
nique may change the dogma. However, our approach is designed
to take care for the acute stroke patient as early as possible after
acute ICA occlusion in order to prevent the patient from chronic
occlusion and further sequelae.
